International Federation of Pharmaceutical Manufacturers & Associations





IFPMA international codes update

Speech to 9th International Pharmaceutical Compliance Congress and Best Practices Forum Brussels 13 May 2015

Dr Brendan Shaw Assistant Director General IFPMA

Email: <u>b.shaw@ifpma.org</u>
Twitter: @shaw brendan



Why is any of this important ?....








Value of Ethical Promotion of Medicines



- Ethical promotion helps ensures that:
 - Healthcare professionals have access to information they require;
 - Patients have access to the medicines they need; and
 - That medicines are prescribed and used to benefit patients worldwide





Member companies































































Environment





Industry changes



Politics, budgets, regulators



Consumers & community





Technology



Many industries facing transparency IFPMA





Pharmaceutical industry







Latest Big Pharma Scandal

on Brownlee @ShannonBrownlee | Jan. 30, 2012 | 1 Comment

¥ Tweet 32

its from drug companies are rampant and perfectly legal, which is why the new e Act is the first step in cleaning up medicine

Share 6

Healtho Like 77 Home Pharma **BioTech** MedTech **BioServices** Specials Home > Pharma > Recent 6 'Big Pharma' frauds China | 6 August 2013 | Analysis | By Sheetal Sukhija Recent 6 'Big Pharma' frauds 70 19 3

in Share

ourself in front of your computer, looking ation about a drug prescribed by your our Internet search tells you that there is a naybe even a generic version available, but just paid top dollar for the brand name also learn that another treatment may be the prescription you just filled. Now ou discover that your doctor gets paid by Email | - Print | RSS facturer to promote the drug to other



Pinit

Read Later

Updated on 8 August 2013



Code, ethics and reputation: current issues







2012 Revision: New Provisions



Fee for Services


Covers
 consultancy,
 market research,
 advisory boards,
 etc.





Support for Continuing Medical Education

(CME) – General statement on the value of CME and requirement that CME must be education in nature, fair and balanced







Company
Procedures and
ResponsibilitiesIncludes scope,
definition, declaration
of involvement and
restrictions on events

*IFPMA/EFPIA/PhRMA/JPMA Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases (2009) & IFPMA/EFPIA/PhRMA/JPMA Joint Position on Publication of Clinical Trial Results in the Scientific Literature (2010)

IFPMA Note for Guidance on Sponsorship of Events and Meetings

Complements Article 7 of the IFPMA Code



IFPMA Note for Guidance on Sponsorship of Events and Meetings

Introduction

Advancing medical knowledge and improving global public health remains a priority for the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) representing the research-based pharmaceutical industry. Collaborations between healthcare professionals and the pharmaceutical industry are essential and ensure that patients have access to the medicines they need and that healthcare professionals have up-to-date comprehensive information about the diseases they treat and the medicines they prescribe. IFPMA members remain committed to activities that provide scientific and educational content to healthcare professionals and advance their medical knowledge and expertise. These activities may take place through various means and media.

The IFPMA Code of Practice sets global standards for industry business practices and includes guiding principles of ethical conduct and promotion as well as requirements for the promotion of medicines to health professionals and interactions with healthcare professionals and other stakeholders. The pharmaceutical industry provides various types of support for a wide range of local, national, and international meetings including sponsorship of healthcare professionals' attendance, provision of grants to medical societies organizing events, hiring of exhibition space, provision of speakers etc. The involvement of pharmaceutical companies also varies and includes arranging its own meetings such as in a local hospital or a clinic to running a satellite symposium at an international meeting organized by a medical society. These activities are covered by Article 7 (Events and Meetings) of the IFPMA Code. The prime reason for attending such meetings should be the educational value and not other factors such as the location, venue, hospitality or timing of the meeting. The choice of location and venue must be appropriate, conducive to the educational objectives and modest. In determining whether to support an event consideration should be given to the educational program, overall cost, facilities offered by the venue, justification for the location, nature of the audience, hospitality and for certain situations, security arrangements. The impression given by all the arrangements should be kept in mind. Pharmaceutical companies might find it helpful to clearly document the reasons as to why they decide to support or run a meeting. Member Associations' codes and member companies' policies and procedures are often even more prescriptive than the IFPMA Code in relation to arrangements for meetings.

The purpose of this document is to provide more information in relation to relevant requirements of the IFPMA Code of Practice. In this respect, the guidance intends to:

- assist all stakeholders, including pharmaceutical companies, member associations, other national trade associations, medical societies, third party event organizers, etc., in the factors to consider when determining whether locations and venues are appropriate, for meetings organized by pharmaceutical companies or third parties such as medical societies and
- provide direction for pharmaceutical companies in the process of assessing the appropriateness
 of their own meetings and their involvement in supporting meetings organized by others, such as
 medical societies, (e.g. by sponsorship of expert speakers, paying for healthcare professionals to
 attend or other type of assistance such as providing a grant, renting exhibition space, etc.).
- Criteria to consider when assessing the appropriateness of the Location of an Event (non-exhaustive)

1. Criteria to consider when assessing the appropriateness of the **Location** of an Event (non-exhaustive)

IFPMA

- 2. Criteria to consider when assessing the appropriateness of the **Venue** of an Event (non-exhaustive)
- 3. Criteria to consider when deciding whether to support an event organized by a third-party such as a medical society (non-exhaustive)
 - Scientific program
 - Entertainment, leisure activities meals
 - Accompanying persons
- 4. Other Criteria to Consider Official meeting materials and websites

^{*}Existing tools and resources

IFPMA Code: Working with Partners

January 2014













Consensus Framework for Ethical Collaboration between Patients' Organisations, Healthcare Professionals and the Pharmaceutical Industry

A Consensus Framework established for ethical collaboration between patients' organisations, healthcare professionals and the pharmaceutical industry, in support of high quality patient care. This Consensus Framework and the accompanying resources are intended to serve as a toolkit for those associations, groups and alliances who wish to develop their own policies. It neither aims to be comprehensive nor does it constitute a single common policy of the organisations involved. The individual policies of the participating organisations set out each organisation's detailed commitments and offer more diverse and in depth information and guidance.

- Joint effort by the patients' organizations, healthcare professional and the pharmaceutical industry
- First global initiative of its kind
- Aims to serve the best interest of patients and ensure ethical behavior from all stakeholders

Code Applicability and General Information


	Affiliation	Country	First Established	First Enforced	Latest Revision	Year of Implementation	Does the code apply to Members?	Does the code apply to Non-members?	ls Code compliance mandatory?	Guiding Principles included?
GLOBAL	IFPMA	GLOBAL	1981	1981	2012	2012	YES	NO	REQUIRED	YES
AMERICAS	CAEME	ARGENTINA	2006	2007	2012	2012	YES	NO	REQUIRED	YES
	INTERFARMA	BRAZIL	2007	2007	2012	2012	YES	YES	REQUIRED	YES
	RX&D	CANADA	1988	N/A	2012	2012	YES	NO	REQUIRED	YES
	CIF	CHILE	2007	N/A	N/A	2007	YES	NO	REQUIRED	NO
	AFIDRO	COLUMBIA	2005	N/A	2010	2010	YES	NO	REQUIRED	YES
	IFI	ECUADOR	1981	2007	2012	2013	YES	NO	REQUIRED	YES
	CETIFARMA/AMIIF	MÉXICO	2005	2006	2012	2013	YES	NO	REQUIRED	YES
	PHRMA	UNITED STATES	2002	2002	2008	2009	YES	YES	VOLUNTARY	NO
ASIA PACIFIC	MEDICINES AUSTRALIA	AUSTRALIA	1960	1960	2012	2013	YES	YES	REQUIRED	YES
	RDPAC	CHINA	2002	2006	2012	2012	YES	NO	REQUIRED	YES
	НКАРІ	HONG KONG	1970	1970	2012	2013	YES	NO	REQUIRED	YES
	OPPI	INDIA	1984	1998	2012	2012	YES	NO	REQUIRED	YES
	IPMG	INDONESIA	2001	2001	2012	2013	YES	NO	REQUIRED	YES
	JPMA	JAPAN	1976	1976	2012	2013	YES	NO	REQUIRED	YES
	KRPIA	KOREA	2001	2006	2011	2011	YES	NO	REQUIRED	YES
	PHAMA	MALAYSIA	1978	1978	2012	2012	YES	NO	VOLUNTARY	YES
	PHAP	PHILIPPINES	1993	1993	2013	2013	YES	YES	REQUIRED	YES
	SAPI	SINGAPORE	1981	1981	2012	2012	YES	NO	REQUIRED	YES
	IRPMA	TAIWAN, R.O.C.	1994	2003	2012	2013	YES	NO	REQUIRED	YES
	PREMA	THAILAND	1987	1987	2012	2012	YES	NO	REQUIRED	YES
EUROPE REGIONAL	EFPIA	EUROPE	1991	1992	2013	2013	YES	YES	REQUIRED	YES
EUROPE	PHARMIG	AUSTRIA	1970	1970	2009	2009	YES	NO	REQUIRED	YES
	AIPM BELARUS	BELARUS	2006	2006	2007	2008	YES	NO	REQUIRED	YES
	PHARMA.BE	BELGIUM	1976	1976	2012	2012	YES	NO	REQUIRED	NO
	LEEM	FRANCE	2011	2011	2012	2012	YES	NO	REQUIRED	YES
	APCRG	GEORGIA	NOT YET	NOTYET	N/A	2013	YES	NO	REQUIRED	YES
	VFA/FSA	GERMANY	2004	2004	2012	2012	YES	YES	REQUIRED	YES
	IPHA	IRELAND	1960	1960	2012	2012	YES	YES	REQUIRED	YES
	FARMINDUSTRIA	ITALY	1978	1978	2012	2012	YES	NO	REQUIRED	NO
	NEFARMA	NETHERLANDS	1994	1994	2012	2012	YES	YES	REQUIRED	YES
	LMI	NORWAY	1994	1994	2011	2012	YES	NO	REQUIRED	YES
	APIFARMA	PORTUGAL	1987	1987	2011	2012	YES	NO	REQUIRED	NO
	AIPM	RUSSIAN FEDERATION	1998	1998	2012	2012	YES	YES	REQUIRED	YES
	FARMAINDUSTRIA	SPAIN	1991	1991	2010	2010	YES	YES	REQUIRED	YES
	LIF	SWEDEN	1969	1969	2012	2012	YES	YES	REQUIRED	NO
	SCIENCEINDUSTRIES	SWITZERLAND	1969	1969	2012	2012	YES	YES	VOLUNTARY	YES
	AIFD TURKEY	TURKEY	2004	2004	2013	2013	YES	NO	REQUIRED	YES
	ABPI/PMCPA	UNITED KINGDOM	1958	1958	2012	2012	YES	YES	REQUIRED	NO
MIDDLE EAST & AFRICA	IPASA	SOUTH AFRICA	1970	1970	2010	2012	YES	NO	REQUIRED	YES

THE IFPMA CODE IS A SELF-REGULATORY MECHANISM WITH A MULTIPLIER EFFECT



DIRECT MEMBERS:

IFPMA members, companies and national associations, are required to adopt the code



INDIRECT MEMBERS: Any company that is a member of at least one IFPMA national association is covered by the IFPMA Code, wherever they operate. This includes pharmaceutical companies, and in some cases medical devices, generic and domestic producers.







The Mexico City Principles

For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector

Challenges Ahead



- Transparency bridging the gap at the global level
 - Disclosure of Payments to healthcare professionals
 - Disclosure of Payments to patient organizations
 - Clinical Research Results (successful and failed)



- Social Media
- Sectoral Discrepancies leveling the playing field among IFPMA members and non-members (i.e. domestic manufacturers, generics, devices, etc.)



The rising tide lifts all the boats

- John F. Kennedy

International Federation of Pharmaceutical Manufacturers & Associations





IFPMA international codes update

Speech to 9th International Pharmaceutical Compliance Congress and Best Practices Forum Brussels 13 May 2015

Dr Brendan Shaw Assistant Director General IFPMA

Email: <u>b.shaw@ifpma.org</u>
Twitter: @shaw brendan